{"product_id":"novartis-bcg-matrix","title":"Novartis Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eNovartis’ BCG Matrix snapshot shows where their big bets and slow burners live—clear signs of which franchises are winning market share and which need tough calls. This preview teases quadrant placement and trends; the full BCG Matrix gives you the exact positioning, data-backed recommendations, and a tactical playbook. Buy the complete report for a polished Word analysis plus an Excel summary you can use in meetings and decisions today.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKisqali (oncology)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKisqali (ribociclib) sits in Stars: high-growth HR+\/HER2- breast cancer with MONALEESA program showing OS benefits (MONALEESA-3 HR 0.67; MONALEESA-7 HR 0.71), driving uptake. It conveys leader vibes as the CDK4\/6 class expands, soaking up promotion and access dollars; Kisqali generated \u0026gt;$2bn sales in 2024. Keep the throttle to convert growth into a blockbuster cash cow and invest to outpace CDK4\/6 rivals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePluvicto (radioligand, prostate)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDemand is surging as radioligand therapy moves mainstream in mCRPC: PSMA PET positivity in mCRPC is ~85% and VISION showed OS hazard ratio 0.62 and rPFS HR 0.40, driving rapid uptake. Capacity build-out and label expansion keep growth hot even as launch‑phase spend (commercialization and site capacity) remains high, so cash in equals cash out for now — classic Star profile. Nail supply reliability and it graduates to cash cow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScemblix (CML)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eScemblix (asciminib) is driving rapid uptake as a targeted switch option with a differentiated safety profile versus ATP‑site TKIs, outperforming expectations in the next‑gen TKI segment. The rising market for next‑generation TKIs favors Scemblix, but cementing leadership requires heavy education and payer access work across oncology clinics and HTA bodies. Novartis must sustain launch momentum and scale commercial and medical affairs to convert early traction into a durable franchise.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCosentyx (immunology) in new indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCosentyx growth has reignited as new approvals in axial psoriatic disease and pediatric indications push share in expanding segments, but it still requires meaningful promotional investment to defend against IL-23 competitors. High visibility and sustained promotional spend have driven scale economies and durable cash generation; Novartis must keep the indication engine running to maintain momentum.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTag: expansion — new axial and pediatric labels\u003c\/li\u003e\n\u003cli\u003eTag: competition — pressure from IL-23 class\u003c\/li\u003e\n\u003cli\u003eTag: investment — high promotion and visibility\u003c\/li\u003e\n\u003cli\u003eTag: strategy — keep indication engine running\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLutathera (NET radioligand)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLutathera, Novartis' lutetium-177 radioligand for gastroenteropancreatic neuroendocrine tumors, in 2024 sustained category-leader status with global net sales exceeding $1 billion, as adoption and geographic reach expanded across Europe, North America and APAC.\u003c\/p\u003e\n\u003cp\u003eMarket penetration remains investment-heavy: manufacturing scale-up and center enablement continue to demand capital and training, but current commercial momentum positions Lutathera as a durable cash generator for Novartis.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024_tag: global net sales \u0026gt;$1B\u003c\/li\u003e\n\u003cli\u003eAdoption_tag: expanding EU\/US\/APAC treatment centers\u003c\/li\u003e\n\u003cli\u003eInvestment_tag: manufacturing and center enablement intensive\u003c\/li\u003e\n\u003cli\u003ePositioning_tag: category leader in a growing radioligand market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCDK4\/6 \u0026gt;$2B, RLT \u0026gt;$1B - PSMA RLT uptake and next-gen TKIs power oncology expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKisqali \u0026gt;$2B 2024 (MONALEESA OS HRs 0.67\/0.71) — high-growth CDK4\/6 leader; PSMA RLT uptake (VISION OS HR 0.62) driving mCRPC expansion; Scemblix rising in next‑gen TKIs; Lutathera \u0026gt;$1B 2024 — capacity and center enablement keep investment high.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 sales\u003c\/th\u003e\n\u003cth\u003eDriver\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eKisqali\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$2B\u003c\/td\u003e\n\u003ctd\u003eMONALEESA OS\u003c\/td\u003e\n\u003ctd\u003eHR 0.67\/0.71\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLutathera\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$1B\u003c\/td\u003e\n\u003ctd\u003eRLT capacity\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix review of Novartis products—strategic moves for Stars, Cash Cows, Question Marks, and Dogs, with invest\/exit guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Novartis BCG Matrix highlighting unit positions to simplify strategy decisions and speed exec alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEntresto (cardiovascular)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEntresto commands majority share in HFrEF with Class I guideline backing and deep physician comfort; global 2024 sales were about $7.0bn, delivering robust margins and steady cash flow. Mature market dynamics mean promotion now primarily defends position, with efficient promo spend maintaining uptake. The product’s reliable cash generation is being milked to fund Novartis pipeline programs and upcoming launches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCosentyx (core psoriasis)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCosentyx remains a Novartis cash cow, generating roughly $4.5bn in annual sales (Novartis reported ~4.5 billion in 2024) with a sticky dermatology patient base and broad payer coverage. Market growth for psoriasis biologics has cooled to low-single-digit growth (~3–5% in 2023–24) but Cosentyx retains solid share. Margins are attractive and promotional spend is disciplined, producing reliable cash flow that funds R\u0026amp;D and portfolio bets elsewhere.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGilenya tail and authorized generics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePost‑LOE Gilenya continues to deliver meaningful residual cash flows via authorized generics and legacy channels, requiring minimal reinvestment while margins on remaining volumes stay high. Forecastable, steady decline fits classic harvest mode, enabling Novartis to allocate proceeds toward growth assets such as oncology and gene therapy. Management uses these proceeds to back higher‑return R\u0026amp;D and M\u0026amp;A priorities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished oncology brands (mature lines)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEstablished oncology brands at Novartis are mature lines with entrenched prescriber habits and stable demand, delivering steady cash flow despite limited growth; Novartis reported group sales near 53 billion USD in 2024, with legacy oncology making a dependable contribution to margins.\u003c\/p\u003e\n\u003cp\u003eMarket share is defended by clinical familiarity, hospital contracts and formulary placement, requiring low incremental commercial spend while quietly funding R\u0026amp;D and newer franchises.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEntrenched demand\u003c\/li\u003e\n\u003cli\u003eLow incremental spend\u003c\/li\u003e\n\u003cli\u003eDefends share via contracts\u003c\/li\u003e\n\u003cli\u003eSteady cash contribution\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVaccines\/diagnostics partnerships and royalties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVaccines and diagnostics partnerships generate non-core but steady royalty streams for Novartis, requiring minimal upkeep and limited capex while smoothing quarterly earnings.\u003c\/p\u003e\n\u003cp\u003eMost agreements are mature with low volatility; in 2024 these cash flows remained capital-light and largely predictable versus core pharma revenue.\u003c\/p\u003e\n\u003cp\u003eMaintain and optimize these assets for yield rather than growth; avoid reallocating significant R\u0026amp;D or M\u0026amp;A capital into this bucket.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003eNon-core, steady royalties\u003c\/li\u003e\n\u003cli\u003eMinimal upkeep, low volatility\u003c\/li\u003e\n\u003cli\u003eCapital-light, earnings smoothing\u003c\/li\u003e\n\u003cli\u003eOptimize, do not overinvest\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMilk flagship cash cows, trim promo spend, redeploy proceeds into high-growth R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEntresto (~7.0bn 2024) and Cosentyx (~4.5bn 2024) are primary cash cows; Gilenya post‑LOE yields high‑margin residual cash with minimal reinvestment. Established oncology lines and vaccines\/diagnostics royalties add steady, capital‑light cash; Novartis group sales ~53bn in 2024. Strategy: milk for yield, keep promo spend efficient, reallocate proceeds to high‑growth R\u0026amp;D.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2024 sales\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEntresto\u003c\/td\u003e\n\u003ctd\u003e~7.0bn\u003c\/td\u003e\n\u003ctd\u003eHFrEF leader, strong margins\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCosentyx\u003c\/td\u003e\n\u003ctd\u003e~4.5bn\u003c\/td\u003e\n\u003ctd\u003eSticky dermatology base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGilenya \u0026amp; oncology\/royalties\u003c\/td\u003e\n\u003ctd\u003eResidual\u003c\/td\u003e\n\u003ctd\u003eCapital‑light, harvest mode\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You’re Viewing Is Included\u003c\/span\u003e\u003cbr\u003eNovartis BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe Novartis BCG Matrix you're previewing is the exact file you'll receive after purchase — no watermarks, no sample notes, just the finished, professional report. It’s formatted for clarity and built for strategic use, so you can present, print, or edit immediately. Once bought, the full document is delivered straight to your inbox with market-backed structure and ready-to-use visuals. No surprises — what you see is what you get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56164171547001,"sku":"novartis-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/novartis-bcg-matrix.png?v=1762726611","url":"https:\/\/portersfiveforce.com\/products\/novartis-bcg-matrix","provider":"Porter's Five Forces","version":"1.0","type":"link"}